ArticleBMC gastroenterology2026
Histopathologic clues to mismatch repair deficiency in colon adenocarcinoma: the role of mucinous component and intratumoral/Crohn-like immune response.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeficient mismatch repair (dMMR) identifies a biologically distinct subset of colon adenocarcinomas with important diagnostic, hereditary, prognostic, and therapeutic implications. This study investigated whether mucinous component and immune response pattern may serve as practical histopathologic clues to dMMR in routine pathology practice.
methodsThis retrospective study included 222 consecutive colon adenocarcinoma resection cases with available mismatch repair (MMR) immunohistochemistry from 2022 to 2025. Clinicopathologic, histomorphologic, and immune response features were evaluated and compared according to MMR status. Multivariable logistic regression was performed to identify factors independently associated with dMMR.
resultsOf 222 tumors, 29 (13.1%) were dMMR and 193 (86.9%) were proficient MMR. dMMR was significantly associated with age < 50 years (40.9% vs. 10.0%, p < 0.001), high grade (25.8% vs. 8.5%, p = 0.010), absence of lymph node metastasis (18.8% vs. 6.7%, p = 0.007), absence of perineural invasion (21.6% vs. 6.4%, p = 0.001), larger tumor size (p < 0.001), fewer metastatic lymph nodes (p = 0.038), and higher lymph node yield (p = 0.019). Intratumoral/Crohn-like immune response was strongly associated with dMMR (33.9% vs. 6.1%, p < 0.001). Tumors with a mucinous component showed a higher dMMR rate than those without (26.2% vs. 10.0%, p = 0.005). All associations that were significant in the unadjusted analyses remained significant after false discovery rate correction (q < 0.05). In the combined histopathologic clue analysis, the dMMR rate increased from 2.3% in tumors with no clue to 28.2% with one clue and 40.0% with both clues. In multivariable analysis, age < 50 years (OR 7.212, p = 0.002), intratumoral/Crohn-like immune response (OR 7.089, p < 0.001), and mucinous component (OR 6.067, p = 0.001) remained independently associated with dMMR.
conclusionsColon adenocarcinomas with a mucinous component and an intratumoral/Crohn-like immune response are enriched for dMMR, whereas tumors lacking both features show a low dMMR rate. These findings provide a detailed histopathologic characterization of a dMMR-enriched phenotype but should not be used to select cases for MMR testing or replace universal testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.